AGENUS INC AGEN Cash Flow

Agenus inc (AGEN)

CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11
Cash flows from operating activities:
Net income (loss)
-174,266	-111,560	-129,557	-117,010	-90,347	-162,044	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss
-	-	-	-	-	-	-	-	-	-	-	-	-112,319	-	-116,478	-88,827	-100,918	-87,881	-98,252	-93,239	-60,870	-42,486	-22,285	-21,494	-24,595	-30,072	-29,735	-28,146	-23,927	-11,324	-11,905	-11,710	-10,544	-23,276	0	0	0
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
6,722	6,662	6,544	6,502	6,370	6,288	6,189	6,057	6,036	6,006	5,851	5,485	5,231	4,947	4,212	3,591	2,756	1,957	1,968	1,880	1,762	1,583	1,157	863	705	586	583	841	1,219	1,622	2,043	2,211	2,235	2,252	0	0	0
Share-based compensation
10,446	9,892	8,774	7,595	7,263	7,625	11,040	11,089	12,256	12,429	11,571	11,999	10,803	13,188	10,921	9,310	10,707	7,438	6,190	6,695	5,211	4,672	4,535	4,024	4,372	4,127	4,015	4,061	4,105	4,303	4,580	4,210	2,912	2,646	0	0	0
Non-cash royalty revenue
34,975	30,424	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash interest expense
46,617	42,201	38,936	35,483	31,358	24,599	20,944	18,183	16,507	18,242	17,697	17,330	16,979	16,530	16,177	13,107	9,378	5,626	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash interest expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	2,109	2,391	3,201	3,141	9,226	8,447	4,808	4,167	0	0	0
Loss on disposal of assets
-	-	-	-	-	-145	-161	-92	-69	-24	0	0	0	-	-	-	-	-	-	-	-	-4	-42	-42	-42	-59	-29	-29	-28	-11	0	0	0	-	-	-	0
Change in fair value of contingent obligations
-1,327	5,805	1,301	2,902	-3,603	-1,335	-4,767	-3,403	2,024	-3,188	-9,278	513	2,099	1,953	10,731	-6,742	6,166	13,567	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gain on issuance of stock for settlement of milestone obligation
-	-	-	-	-	-	-	-	-	566	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change in fair value of contingent obligations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	0	0	0	-	-	-	-	-	-	-	-
Loss on modification of debt
0	-	-	-	-	-10,767	0	0	0	-	-	-	-	-	-	-	-	-154	0	0	0	-	0	0	-3,322	-3,322	0	0	0	-	-	-	-	-	-	-	-
Gain on sale of investment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
Changes in operating assets and liabilities:
Accounts receivable
1,848	15,355	-3,740	-8,714	-332	-196	3,877	6,976	-5,645	-10,217	-8,092	-5,424	-3,396	1,549	2,579	4,944	7,645	9,331	7,232	3,952	2,055	-1	-1	-202	-163	-551	370	294	222	552	-369	-92	-58	-35	0	0	0
Inventories
-	-	-	-	-	-24	0	0	0	-	-	-	-	-	-	-	-	-7	-7	-7	88	95	92	91	-16	-16	-20	-17	-5	-4	0	0	0	-	-	-	0
Prepaid expenses
-11,116	-11,792	-4,040	654	7,096	8,210	3,744	3,974	4,397	8,453	7,761	6,179	3,867	650	1,076	1,112	541	703	522	558	948	254	428	7	50	112	214	357	619	9	-330	-449	-596	-168	0	0	0
Accounts payable
1,816	-234	5,584	9,340	7,324	5,366	3,521	4,540	-95	1,646	2,699	-1,280	1,606	419	129	2,344	-1,869	2,668	1,185	1,313	2,043	-45	494	-130	523	189	-111	-248	135	-181	-19	288	-113	105	0	0	0
Deferred revenue
-4,603	53,900	63,218	53,208	56,704	-397	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred revenue
-	-	-	-	-	-	-	-	-	-	-	-	-3,054	-	-5,794	-7,625	-9,215	15,957	17,550	18,572	20,713	-3,610	-2,923	-1,834	-1,781	-1,474	121	117	215	2,707	949	960	963	-1,531	0	0	0
Accrued liabilities and other current liabilities
1,231	7,097	8,487	3,941	4,222	3,303	1,335	310	-4,425	-4,849	5,973	6,858	8,752	18,275	7,516	11,439	14,416	9,565	9,095	1,650	841	-1,316	-2,250	2,051	-543	1,916	1,341	653	394	542	-25	-180	124	-269	0	0	0
Other operating assets and liabilities
-6,464	-1,429	-1,626	-237	947	113	236	-204	3,114	2,329	4,866	4,167	2,916	2,155	283	1,258	574	11,538	10,712	8,355	11,586	685	465	2,646	-79	-183	-1,567	-1,308	-988	-747	868	641	587	591	0	0	0
Net cash (used in) provided by operating activities
-129,774	-18,682	-22,714	-19,431	-14,257	-131,095	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-17,266	-16,470	-14,154	1,012	109	347	-332	-16,248	0	0	0
Cash flows from investing activities:
Net cash used in operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-73,258	-	-83,435	-77,626	-72,003	-47,175	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from sale of plant and equipment
-	-	-	-	-	6	6	5	10	120	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	23	0	0	0
Cash acquired in acquisition
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	514	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Purchases of plant and equipment
3,800	4,657	4,202	4,183	3,603	3,597	3,749	3,890	4,197	3,120	6,694	10,761	11,399	12,519	8,964	5,232	4,804	3,591	4,532	3,572	2,970	2,819	1,171	993	608	813	951	759	480	103	-101	-60	11	54	0	0	0
Purchases of available-for-sale securities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	4,998	0	0	0
Proceeds from sale of available-for-sale securities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchases of held-to-maturity securities
-	-	-	-	-	-	-	-	-	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from securities held-to-maturity
-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in investing activities
-	-	-	-	-	-	-	-	-	-	-	-	48,794	-	-21,016	-47,304	-81,903	-31,232	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from sale of available-for-sale securities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	0	0	0	-	-	-	-	-	-	-	-
Net cash used in investing activities
-3,800	-4,657	-4,202	-4,182	-3,602	-3,591	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-299	-629	-480	-103	-99	-63	5,002	-29	0	0	0
Cash flows from financing activities:
Net proceeds from sale of equity
65,123	30,000	33,639	47,024	69,661	44,919	43,162	29,777	8,981	65,560	0	0	0	-	-	-	-	109,669	109,669	109,683	35,125	56,792	60,124	80,980	83,130	26,462	23,131	5,514	7,705	10,464	0	0	0	-	-	-	-
Proceeds from employee stock purchases and option exercises
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net proceeds from issuance of common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Payment of long-term debt
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Proceeds from employee stock purchases and option exercises
-	-	-	-	-	-	-	0	1,743	-	924	1,054	1,050	1,183	1,104	764	1,303	1,975	2,065	1,849	1,276	251	150	137	152	104	105	99	101	78	76	69	52	82	0	0	0
Financing of plant and equipment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-46	-48	-48	-38	0	0	0	-	-	-	-
Proceeds from issuance of long-term debt
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	109,000	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from sale of future royalties
-	-	-	-	-	204,878	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Transaction costs from sale of future royalties and milestones
-	-	-	-	-	494	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Repayments of debt
0	-	-	-	-	161,847	0	0	0	-	-	-	-	-	-	-	-	1,111	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payment of contingent purchase price consideration
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	8,180	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payment under a purchase agreement for in-process research and development
-	-	-	-	-	-	-	-	-	-	-	-	-	5,000	0	0	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payment of preferred stock dividends
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	592	-395	0	395	790	0	0	0
Payment of finance lease obligation
1,459	320	322	305	293	283	307	326	329	331	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payment of contingent royalty obligation
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Payments of convertible notes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
Net cash provided by financing activities
-	-	-	-	-	-	-	-	-	-	-	-	60,175	-	-4,434	73,491	152,921	189,579	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from Issuance of Debt
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from (Repayments of) Debt
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Payment of contingent royalty obligation
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by financing activities
66,839	31,323	73,483	101,943	124,592	128,286	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	23,012	5,089	7,263	9,811	10,016	13,156	9,284	7,244	0	0	0
Effect of exchange rate changes on cash
713	770	537	224	-774	-733	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net increase (decrease) in cash and cash equivalents
-66,022	8,754	47,104	78,554	105,959	-7,133	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Effect of exchange rate changes on cash
-	-	-	-	-	-	-	-	-	-	-	-	-178	-	186	172	12	-183	204	89	574	599	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-
Net (decrease) increase in cash and cash equivalents
-	-	-	-	-	-	-	-	-	-	-	-	35,533	-	-108,700	-51,266	-973	110,988	145,752	76,394	5,812	-1,637	8,181	34,825	56,277	5,883	5,447	-12,011	-7,371	10,720	10,026	13,440	13,954	-9,034	0	0	0
Supplemental cash flow information:
Cash paid for interest
1,116	1,224	1,258	1,236	1,207	1,171	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash paid for interest
-	-	-	-	-	-	-	-	-	-	-	-	1,120	-	1,120	1,121	1,127	1,053	914	795	683	675	744	794	770	579	0	0	0	-	-	-	-	-	-	-	-
Supplemental disclosures - non-cash activities:
Purchases of plant and equipment in accounts payable and accrued liabilities
0	-	-	-399	190	300	867	1,416	787	968	-82	989	826	695	993	63	438	105	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Lease right-of-use assets obtained in exchange for new operating lease liabilities
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Lease right-of-use assets obtained in exchange for new finance lease liabilities
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Issuance of common stock, $0.01 par value, for acquisition of 4-Antibody AG
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	0	-	-	-	-	-	-	-	-
Contingent purchase price consideration
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	9,721	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-
Deemed dividend on series A convertible preferred stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,906	2,906	2,906	2,906	0	0	0	0	-	-	-	-
Convertible note adjustment to equity for conversion option
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5,580	0	0	0
Reclassification of derivative liability into equity
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	755	0	0	0
Issuance of common stock, $0.01 par value, as payment of long-term debt
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Payment to Consultant [Member]
Issuance of common stock
55	81	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-